A clinical and molecular genetic study of hypophosphatemic rickets in children.
X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets, hereditary hypophosphatemic rickets with hypercalciuria, and tumor-induced osteomalacia share clinical and biochemical features, and are collectively referred to as hypophosphatemic rickets (HR). Recently, the molecular bases of HR were elucidated. A review of medical records and mutational analyses of the PHEX and FGF23 genes were performed on 17 unrelated Korean children with HR. The male-to-female ratio was 3:14, and 5 patients were familial. Initial laboratory tests revealed typical features of HR. Seven different PHEX mutations were detected in 8 patients: 2 missense mutations, 2 nonsense mutations, and 3 short deletions. No functional FGF23 mutation was detected in any patient. Patients with the PHEX mutation tended to have more severe skeletal disease than those without. Of the patients with this mutation, no genotype-phenotype correlation and no gene dosage effect were noted. Treatment with vitamin D and phosphate resulted in only a partial growth improvement in most cases, and was frequently complicated by hypercalciuria, hypercalcemia, nephrocalcinosis, or hyperparathyroidism. Renal glycosuria was detected in six cases and was associated with more severe skeletal disease. We conclude that current HR treatment is not fully safe or effective, and that close monitoring of treatment effectiveness and for complications should be performed during long-term treatment. No genotype-phenotype correlation in XLH was detected in this study, but a large-scaled study on this topic is warranted. The large proportion of patients with a normal genetic study suggests the possibility of other causative gene(s).
Cho
Hee Y
HY
Department of Pediatrics, Seoul National University Children's Hospital, Seoul 110-744, Korea.
Lee
Bum H
BH
Kang
Ju H
JH
Ha
Il S
IS
Cheong
Hae I
HI
Choi
Yong
Y
D002675:Child, Preschool; D041321:Chromosomes, Human, X; D018389:Codon, Nonsense; D004252:DNA Mutational Analysis; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000235:genetics; D017353:Gene Deletion; D005838:Genotype; D006029:Glycosuria / Q000378:metabolism; D006801:Humans; D007015:Hypophosphatemia, Familial / Q000175:diagnosis* / Q000235:genetics*; D007223:Infant; D008297:Male; D009154:Mutation; D020125:Mutation, Missense; D053402:PHEX Phosphate Regulating Neutral Endopeptidase; D010641:Phenotype; D010710:Phosphates / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011506:Proteins / Q000235:genetics; D014807:Vitamin D / Q000494:pharmacology
D018389:Codon, Nonsense; C000717427:FGF23 protein, human; D010710:Phosphates; D011506:Proteins; D014807:Vitamin D; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D053402:PHEX Phosphate Regulating Neutral Endopeptidase; C506231:PHEX protein, human